This is the golden age of gene editing. Our view of gene editing company Editas Medicine (EDIT) is positive but a stock and a company are two different things. This stock has been highly pumped recently. This provided a trading opportunity from the short side. The stock was sold short at an average price of $88.51. Now there are nice gains as the stock has fallen.
Editas Medicine (EDIT) is trading at $69.26 as of this writing. Depending upon the quantity held and personal preference, consider taking more partial profits in the zone of $67 to $70.57. Consider continuing to hold the rest.